Keyphrases
18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography
7%
2-cycles
7%
4-cycle
7%
Cell Proliferation
15%
Chemoimmunotherapy
15%
Chemotherapy
7%
Clinical Setting
7%
Combined Modality Therapy
7%
Diffuse Large B-cell Lymphoma (DLBCL)
80%
Disease Progression
15%
Early Response
7%
Event-free Survival
15%
Fluorodeoxyglucose
7%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
15%
Fluorodeoxyglucose Positron Emission Tomography/computed Tomography
46%
Fluorothymidine
80%
Histological Markers
7%
Inflammatory Changes
15%
Ki-67 Index
7%
Lymphoma
15%
Lymphoma Patients
22%
Macrophages
7%
Molecular Imaging
7%
Monocyte Infiltration
7%
Negative Predictive Value
18%
Overall Survival
7%
Patient Management
13%
Patient Survival
7%
Patient's Will
15%
Persistent Disease
7%
Positive Predictive Value
22%
Positron Emission Tomography
10%
Positron Emission Tomography-computed Tomography (PET-CT)
80%
Predictive Value
7%
Prognostic Tool
7%
R-CHOP
7%
R-CHOP Chemotherapy
7%
Radiation Therapy
7%
Recent Advances
7%
Restaging
7%
Staging Procedures
7%
Therapeutic Modalities
7%
Treatment Monitoring
80%
Tumor-specific
15%
Medicine and Dentistry
Biopsy
8%
Cell Proliferation
11%
Chemoimmunotherapy
11%
Computer Assisted Tomography
5%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
11%
Diffuse Large B-Cell Lymphoma
100%
Disease
5%
Disease Exacerbation
11%
Event Free Survival
11%
False Positive Result
5%
Fluorodeoxyglucose
55%
Fluorodeoxyglucose F 18
5%
Macrophage
5%
Molecular Imaging
5%
Monocyte
5%
Multimodality Cancer Therapy
5%
Neoplasm
5%
Overall Survival
5%
Patient Care
11%
Positron Emission Tomography
23%
Positron Emission Tomography-Computed Tomography
100%
Radiation Therapy
5%
Radioactive Tracer
5%
Specific Tumor
5%
Neuroscience
B Cell
100%
Cell Proliferation
11%
Chemoimmunotherapy
11%
CHOP
11%
Fluorine-18
5%
In Vivo
5%
Macrophage
5%
Molecular Imaging
5%
Positron Emission Tomography
23%
Positron Emission Tomography-Computed Tomography
100%
Radiation Therapy
5%